GGrantIndex
Sort

23,748 grants matching melanoma

Molecular basis of melanocytic nevi

$167,940
Maija Helena Tuulia Kiuru · University Of California At Davis · K23 · FY2022 · AR

Molecular basis of melanocytic nevi

$167,940
Maija Helena Tuulia Kiuru · University Of California At Davis · K23 · FY2023 · AR

A novel cellular tumor vaccine strategy for mutant IDH1 glioma

$167,921
Michael D Gunn · Duke University · P50 · FY2021 · CA

Exploiting the Unique T Cell Response to CMV for a Cancer Vaccine

$167,845
Ann B Hill · Oregon Health & Science University · R21 · FY2010 · CA

Activation of pDCs in Murine Tumor Models

$167,833
Willem W Overwijk · University Of Tx Md Anderson Can Ctr · P01 · FY2008 · CA

Development of Immunotherapeutic Strategies in the Treatment of Lung Cancer

$167,791
Scott J Antonia · H. Lee Moffitt Cancer Ctr & Res Inst · K24 · FY2010 · CA

MATCHMAKERS

$167,757
Ton Schumacher · Netherlands Cancer Institute · OT2 · FY2024 · CA

Core D: Animal Experimentation & Wound Healing

$167,746
Kevin D Cooper · Case Western Reserve University · P30 · FY2015 · AR

Quantification of the environmental UVA exposure

$167,631
Michael G Kimlin · Queensland University Of Technology · R01 · FY2008 · CA

Quantification of the environmental UVA exposure

$167,631
Michael G Kimlin · Queensland University Of Technology · R01 · FY2007 · CA

NAC for melanoma chemoprevention

$167,619
Douglas Grossman · University Of Utah · R21 · FY2010 · AR

Immunogene Therapy of Mesothelin Expressing Tumors Using Engineered T Cells

$167,527
Carl H. June · University Of Pennsylvania · P01 · FY2015 · CA

Immunogene Therapy of Mesothelin Expressing Tumors Using Engineered T Cells

$167,527
Carl H. June · University Of Pennsylvania · P01 · FY2016 · CA

Systems analysis of phenotypic switch in control of cancer invasion

$167,500
Andre Levchenko · Yale University · U54 · FY2016 · CA

Genetically Modified Natural Killer Cells for Cancer Immunotherapy

$167,476
Branden S Moriarity · University Of Minnesota · R21 · FY2018 · CA

Diagnosing Emergence of Kinase Inhibitor Resistance on a Microchip

$167,475
Thomas G Graeber · University Of California Los Angeles · R21 · FY2012 · CA

Hereditary cancer predisposition syndromes and uveal melanoma

$167,475
Mohamed H. Abdel-Rahman · Ohio State University · R21 · FY2016 · CA

Targeting melanoma hypoxia with lactic acid bacterium L. lactis

$167,475
Jorge G Gomez-Gutierrez · University Of Louisville · R21 · FY2018 · CA

Post-transplant Cutaneous Squamous Cell Carcinoma and Macrophage Migration Inhibitory Factor

$167,475
Tatiana M Oberyszyn · Ohio State University · R21 · FY2017 · CA

IL-27-based cancer vaccination approach for cancer immunotherapy

$167,475
Xue-Feng Bai · Ohio State University · R21 · FY2015 · CA

Role of senescent fibroblasts in UVB-induced carcinogenesis

$167,475
Dan F Spandau · Indiana University Indianapolis · R21 · FY2010 · CA

T cell responses shared among triple negative breast cancer patients

$167,411
Jill E Slansky · University Of Colorado Denver · R21 · FY2019 · CA

Admin. Suppl. for NCI CCSG/Moonshot Grant to Develop Immune Radiation Response Index (iRRI) for Immune Cells from Normal and Tumor Microenvironments

$167,344
Raphael E. Pollock · Ohio State University · P30 · FY2022 · CA

Targeting Lipid Metabolism in the Tumor Microenvironment

$167,328
Ashani T Weeraratna · Wistar Institute · P01 · FY2023 · CA

Specimen Resource Core

$167,269
Ruth Halaban · Yale University · P50 · FY2012 · CA